Nokihara, Hiroshi
Yamada, Yasuhide
Fujiwara, Yutaka
Yamamoto, Noboru
Wakui, Hiroshi
Nakamichi, Shinji
Kitazono, Satoru
Inoue, Kohei
Harada, Akiko
Taube, Tillmann
Takeuchi, Yoshito
Tamura, Tomohide
Article History
Received: 10 June 2015
Accepted: 1 November 2015
First Online: 2 December 2015
Compliance with ethical standards
:
: The trial was approved by National Cancer Center Hospital’s Institutional Review Board and conducted in compliance with the principles laid down in the Declaration of Helsinki, in accordance with the International Conference on Harmonisation Harmonised Tripartite Guideline for Good Clinical Practice (GCP) and in accordance with relevant Boehringer Ingelheim standard operating procedures and Japanese GCP. All participating patients gave written informed consent.
: Hiroshi Nokihara received honoraria from Sanofi, Eli Lilly, Boehringer Ingelheim, Pfizer, Taiho Pharmaceutical, and Ono Pharmaceutical, and research support from Merck Serono, Pfizer, Taiho Pharmaceutical, Esai Co., Ltd, Chugai Pharmaceutical Co., Ltd, Eli Lilly, Novartis, Daiichi Sankyo, GlaxoSmithKline, Yakult Pharmaceutical Industry Co., Ltd, Quintiles, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, and Ono Pharmaceutical. Yasuhide Yamada received honoraria from Taiho Pharmaceutical, Yakult Pharmaceutical Industry Co., Ltd, and Chugai Pharmaceutical Co., Ltd, and grants/patents from AstraZeneca, Novartis, Chugai Pharmaceutical Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Taiho Pharmaceutical, Daiichi Sankyo, and Merck Serono. Noboru Yamamoto received honoraria from Chugai Pharmaceutical Co., Ltd, Eli Lilly, AstraZeneca, and Sanofi, and grants/patents from Chugai Pharmaceutical Co., Ltd, Eli Lilly, Taiho Pharmaceutical, Esai Co., Ltd, Quintiles, Astellas Pharma, Bristol-Myers Squibb, Novartis, Daiichi Sankyo, Pfizer, and Takeda Pharmaceutical Company Ltd. Tillmann Taube is an employee of Boehringer Ingelheim Pharma GmbH & Co KG. Tomohide Tamura received honoraria from Boehringer Ingelheim. All other authors disclose no potential conflicts of interest.